Navigation Links
Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
Date:10/27/2011

re information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

The anticipated news release and conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the adequacy of the Company's capital to support the Company's operations, the potential of the Company's ADASUVE NDA resubmission to adequately address the issues in the Complete Response Letter, the timing of the FDA's review of the NDA, the eventual prospects that ADASUVE will be approved for marketing in the U.S., and the timing and prospects for regulatory approval to market ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 Patterson Medical, ... (Nasdaq: PDCO ), is now an independent ... acquisition of Patterson Medical by Madison Dearborn Partners ... its name for a transition period before rebranding ... and sports medicine products.  With the focused resources ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by AstraZeneca plc, ... an important drug for the treatment of schizophrenia. ... quetiapine was listed in the Catalogue of Drugs ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on ... their offering. Developed by Novo Nordisk, ... is an important drug for the treatment of ... a fast- acting insulin analog, starts working fast ...
Breaking Medicine Technology:Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3China Quetiapine Market Investigation Report 2010-2019 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... -- Peregrine,s Second Phase II Bavituximab Cancer Trial Is Evaluating the, ... ... Paclitaxel --, TUSTIN, Calif., June 30 Peregrine,Pharmaceuticals, Inc. ... in a Phase II trial designed to evaluate the safety,and efficacy of ...
... Meeting with FDA Set for Sept. 29, ... (Nasdaq: TPTX ) today announced that data ... American Headache Society showed that, in,addition to meeting ... two,hours, the company,s lead AMPA/kainate-type glutamate receptor antagonist,tezampanel, ...
Cached Medicine Technology:Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 2Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 3Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 4Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel 2Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel 3
(Date:8/28/2015)... ... 28, 2015 , ... The 6th Annual Survivor in the City, Chicago ... yet another accolade to its cadre of widespread support—an official letter of support and ... of the medical community and the University of Illinois at Chicago’s Department of Neurosurgery, ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... On May ... Michigan, joined as sponsor of the “Music With A Mission” benefit concert in Mendon, ... the event was to raise money to support music education programs in the underfunded ...
(Date:8/28/2015)... ... August 28, 2015 , ... Loved ... might personally be struggling with chemical dependency, may be able to find some ... a results-driven holistic treatment center for addiction located in Western Michigan. Focusing on ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... of high grade protein with zero fat, carbs, sugar, gluten, lactose or caffeine ... a finalist for the 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer ...
(Date:8/28/2015)... ... August 28, 2015 , ... “ Frequentz ” was featured on ... and coolest applications on the market for iOS, Android, and Windows. Joe Toohey, the ... how this software allows businesses to track product movement from beginning to end. , ...
Breaking Medicine News(10 mins):Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:Track Product Movement from Beginning to End with Frequentz 2
... MVP Health Care, a leading,regional not-for-profit health ... Vermont and New Hampshire, has selected IncentOne, the ... to MVP and,Preferred Care health plan members through ... Care health plans that utilize the "WellStyle Extras",option, ...
... their teachers from four counties, San,Bernardino, Riverside, Inyo and ... Nov. 6 On Sunday, November 9,2008 at 1 ... Stater Bros. Markets, in conjunction with KFRG radio stations ... children on the field,of the Arrowhead Credit Union Stadium ...
... different approaches seek to interfere with mechanisms that inhibit cell ... in the spinal cord and brain can,t be repaired now ... get them to grow again are being proposed by separate ... is to interfere with the built-in mechanisms that prevent nerve ...
... 6 Medicaid Health Plans of,America (MHPA), ... Medicaid health plans, today extended its congratulations ... in becoming the 44th,President of the United ... on his historic,victory," stated MHPA,s Executive Director ...
... Local union outpaces national SEIU in securing rights for ... - Workers at six,Sacramento-area nursing homes voted by more ... Horizon West, achieving important gains,for residents and workers that ... Over 500 members of SEIU United Healthcare Workers-West ...
... Hands Helps Improve Healing, Reduce ... Post-Op Swelling and ... today,the release of its breakthrough Hand Wrap for use with ... Wrap,dramatically increases physicians, and patients, treatment options by,extending Game Ready,s ...
Cached Medicine News:Health News:MVP Health Care and IncentOne Partner to Provide Member Incentives for MVP and Preferred Care 'WellStyle Extras' Program 2Health News:Stater Bros. Charities, KFRG Radio Stations and Loma Linda University Children's Hospital Will Present More Than 1,100 Brand-New Bikes to 4th Grade Students! 2Health News:New Pathways Studied to Repair Nerves 2Health News:New Pathways Studied to Repair Nerves 3Health News:United Healthcare Workers Win New Contract with Horizon West 2Health News:United Healthcare Workers Win New Contract with Horizon West 3Health News:Game Ready(TM) Announces New Hand Treatment 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: